Zidovudine

證據等級: L5

預測適應症: 6 個

One-Sentence Summary

Zidovudine (AZT) is the original nucleoside reverse transcriptase inhibitor used in antiretroviral therapy for HIV infection. The TxGNN model predicts strong applicability to AIDS-Related Complex (ARC) — historically AZT’s first ever approved clinical indication — with 50 clinical trials and 20 publications currently supporting this direction, making this a validation of known efficacy rather than a novel off-label discovery.

Quick Overview

Item	Content
Original Indication	Not documented in the current registry dataset; literature evidence describes zidovudine as an antiretroviral used for HIV infection/AIDS
Predicted New Indication	AIDS-Related Complex
TxGNN Prediction Score	99.19%
Evidence Level	L1
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed formal mechanism-of-action documentation is not available in the current dataset. However, the evidence pack’s own rationale confirms zidovudine’s core pharmacology: it inhibits HIV reverse transcriptase, blocking viral replication. AIDS-Related Complex represents the early-to-moderate immunodeficiency stage of HIV infection, preceding full-blown AIDS.

Notably, this predicted indication is not a distant repurposing target — the underlying evidence explicitly states that ARC was historically AZT’s first-ever approved clinical use. This means the TxGNN model has successfully “rediscovered” a real, well-established indication for this drug, which serves as a strong internal validation of the prediction methodology rather than an entirely new therapeutic hypothesis.

Because the pharmacological target (HIV reverse transcriptase) is identical between HIV infection, ARC, and full AIDS, the mechanistic link is direct and requires no cross-disease extrapolation — the entire disease continuum shares the same causative virus and the same drug target.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00000637	Phase 3	Completed	819	AZT vs. ddI vs. AZT+ddI in symptomatic HIV-infected children; compared survival and disease progression
NCT00002334	Phase 3	Completed	3000	AZT alone vs. AZT+ddC vs. AZT+saquinavir vs. triple combination in treatment-naive HIV patients
NCT00000679	Phase 2	Completed	600	ddC vs. zidovudine in AIDS/advanced ARC comparing efficacy and safety profile
NCT00000979	Phase 2	Completed	1500	ddI vs. zidovudine in AIDS, advanced ARC, or asymptomatic infection with CD4 < 200
NCT00002124	Phase 3	Completed	1250	Delavirdine + zidovudine vs. zidovudine alone in HIV-1 infected patients, CD4 200–500
NCT00002290	N/A	Completed	N/A	Concurrent Retrovir (zidovudine) + Zovirax (acyclovir) vs. zidovudine alone in early symptomatic HIV infection
NCT00000831	Phase 2	Completed	280	Virologic responses to new nucleoside regimens after prolonged zidovudine or ddI monotherapy
NCT00000986	Phase 1	Completed	18	Safety, tolerance, and immunology of IL-2 + zidovudine combination in AIDS/ARC patients
NCT00002081	N/A	Completed	N/A	Open-label ddC + zidovudine combination program for advanced HIV disease with toxicity monitoring
NCT00002035	N/A	Completed	300	Continued zidovudine vs. ddI in AIDS/ARC patients showing clinical deterioration on zidovudine

(50 trials total are on record for this indication; the above 10 represent the most clinically pivotal.)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
3299089	1987	RCT	N Engl J Med	Landmark double-blind, placebo-controlled trial establishing AZT efficacy in AIDS/ARC (Fischl et al.)
2677429	1989	RCT	JAMA	Long-term follow-up: prolonged zidovudine therapy improved survival in AIDS/ARC patients
1777174	1991	RCT	AIDS	European-Australian double-blind trial: zidovudine ± acyclovir for AIDS-related complex
2159707	1990	RCT	Am J Med	ACTG Phase I/II study: ddC + zidovudine combination in AIDS and advanced ARC
2159705	1990	RCT	Am J Med	Alternating/intermittent zidovudine + ddC regimens in AIDS/ARC treatment
2191113	1990	RCT	J Acquir Immune Defic Syndr	Placebo-controlled trial showing quality-of-life benefit of zidovudine in AIDS/ARC
8096703	1993	RCT	AIDS	Double-blind randomized trial: zidovudine alone vs. cotherapy with acyclovir in AIDS/ARC
3059187	1988	RCT	N Engl J Med	Double-blind trial assessing neuropsychological outcomes of zidovudine in AIDS/ARC
1974727	1990	RCT	Rev Infect Dis	Phase I dose-finding trial of ddI in AZT-intolerant AIDS/ARC patients
1894937	1991	Cohort	J Infect Dis	Zidovudine treatment associated with improved pneumococcal vaccine antibody response in AIDS/ARC

US Market Information

No marketing authorization records are currently on file. According to the regulatory dataset, zidovudine’s status is Not Marketed, with 0 licenses registered in this jurisdiction.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The evidence base is exceptionally strong (Evidence Level L1) — 50 clinical trials, including multiple completed Phase 3 RCTs, and 20 supporting publications — and this indication corresponds to the drug’s own historically approved use, giving high mechanistic and clinical confidence. However, a Blocking data gap on TFDA-equivalent label warnings/contraindications prevents completion of the safety initial assessment (S1), and the drug currently has no active marketing authorization in this jurisdiction.

To proceed, the following is needed:

Official package insert / label warnings and contraindications (Blocking gap, DG001)
Formal mechanism-of-action documentation from DrugBank or equivalent source (High priority gap, DG002)
Clarification of current marketing/licensing pathway, since the drug is presently unmarketed with zero NDAs on record
Confirmation of whether “AIDS-Related Complex” should be treated as a label-expansion/reconfirmation case rather than a novel repurposing indication, given its historical approval status
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.